Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys

Last Updated: June 28, 2022

Investigational Drug Information for Losmapimod


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Losmapimod?

Losmapimod is an investigational drug.

There have been 15 clinical trials for Losmapimod. The most recent clinical trial was a Phase 3 trial, which was initiated on June 3rd 2014.

The most common disease conditions in clinical trials are Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophies, and Acute Coronary Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and Royal Brompton & Harefield NHS Foundation Trust.

There are one hundred and thirteen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Losmapimod
TitleSponsorPhase
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)Fulcrum TherapeuticsPhase 3
Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsFulcrum TherapeuticsPhase 1
Losmapimod Safety and Efficacy in COVID-19Fulcrum TherapeuticsPhase 3

See all Losmapimod clinical trials

Clinical Trial Summary for Losmapimod

Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod

See all Losmapimod clinical trials

US Patents for Losmapimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Losmapimod See Plans and Pricing Compounds .alpha..sub.v.beta..sub.6 integrin antagonists GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) See Plans and Pricing
Losmapimod See Plans and Pricing IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) See Plans and Pricing
Losmapimod See Plans and Pricing Compounds alpha v beta 6 integrin antagonists GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) See Plans and Pricing
Losmapimod See Plans and Pricing IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) See Plans and Pricing
Losmapimod See Plans and Pricing Inhalable pharmaceutical compositions iCeutica Pty Ltd. (Iluka, WA, AU) See Plans and Pricing
Losmapimod See Plans and Pricing 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors Chiesi Farmaceutici S.p.A. (Parma, IT) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Losmapimod

Drugname Country Document Number Estimated Expiration Related US Patent
Losmapimod Argentina AR101995 2034-09-26 See Plans and Pricing
Losmapimod Australia AU2015320859 2034-09-26 See Plans and Pricing
Losmapimod Brazil BR112017006253 2034-09-26 See Plans and Pricing
Losmapimod Canada CA2962326 2034-09-26 See Plans and Pricing
Losmapimod China CN107074849 2034-09-26 See Plans and Pricing
Losmapimod European Patent Office EP3197893 2034-09-26 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.